Targets › CTNNB1
3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Other, Oncology, Hematology; next expected readout Dec 2026.
Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. (UniProt, P35222)
Open in Phaseline: the race on CTNNB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kiminori Kimura, MD | Pri-724 CBP/beta catenin inhibitor | CREBBP, CTNNB1 | Phase 2 | Liver Cirrhosis | Nov 2027 |
| Stanford University | Niclosamide Wnt/β-catenin pathway inhibitor | CTNNB1 | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
| CTNNB1 Foundation | Urbagen AAV9-mediated gene replacement therapy encoding human β-catenin protein | CTNNB1 | Phase 1 | CTNNB1 Neurodevelopmental Syndrome | Dec 2032 |
CTNNB1 Neurodevelopmental Syndrome (1) Acute Myeloid Leukemia (AML) (1) Liver Cirrhosis (1)
small molecule (2), mixed (1)
CTNNB1 Foundation (1) Stanford University (1) Kiminori Kimura, MD (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.